Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Longbio Pharma (Suzhou) CoHKSE:01779 +5.51%10 Market Cap is HK$8,624.40 Mil as of Aug. 09, 2026. GuruFocus rates HKSE:01779 with a GF Score™ of 10/100. Among 1,420 Biotechnology companies, Longbio Pharma (Suzhou) Co ranks better than 80.42% on this metric.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Longbio Pharma (Suzhou) Co's Enterprise Value for Today is HK$8,446.36 Mil.
Longbio Pharma (Suzhou) Co (HKSE:01779) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Longbio Pharma (Suzhou) Co Market Cap Related Terms
Longbio Pharma (Suzhou) Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longbio Pharma (Suzhou) Co Market Cap Chart
Longbio Pharma (Suzhou) Co Annual Data
Trend
Dec24
Dec25
Market Cap
0.00
0.00
Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24
Dec25
Market Cap
0.00
0.00
HKSE:01779 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Longbio Pharma (Suzhou) Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longbio Pharma (Suzhou) Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Longbio Pharma (Suzhou) Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Longbio Pharma (Suzhou) Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longbio Pharma (Suzhou) Co (HKSE:01779) has a Market Cap of HK$8,624.40 Mil as of Aug. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Longbio Pharma (Suzhou) Co and its competitors. According to the industry distribution chart, Longbio Pharma (Suzhou) Co ranks #278 out of 1420 companies in the Biotechnology industry, placing it in the top 19.6%.
Is Longbio Pharma (Suzhou) Co's Market Cap too high?
Longbio Pharma (Suzhou) Co's current Market Cap is HK$8,624.40 Mil. Based on the distribution chart, Longbio Pharma (Suzhou) Co ranks #278 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Longbio Pharma (Suzhou) Co ranks #278 out of 1420 companies for Market Cap. This places Longbio Pharma (Suzhou) Co in the top 20% of its industry — outperforming the majority of peers. The industry median Market Cap is 116.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.96, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Longbio Pharma (Suzhou) Co and its competitors. For the Biotechnology industry, the median Market Cap is 116.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longbio Pharma (Suzhou) Co's current Market Cap is HK$8,624.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current Market Cap of HK$8,624.40 Mil. The current Market Cap is HK$8,624.40 Mil. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current Market Cap is HK$8,624.40 Mil as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score
Get the complete analysis for HKSE:01779
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01779 has been successfully added to your 
